Chemomab Therapeutics (CMMB) Restructuring Costs (2020)
Chemomab Therapeutics' (CMMB) quarterly Restructuring Costs came in at -$699000.0 in Q4 2020, down 984.81% quarter-over-quarter from $79000.0 in Q3 2020.
Powered by 
Analysis
Chemomab Therapeutics (CMMB) Restructuring Costs (2020) Analysis & Trends
Chemomab Therapeutics (CMMB) has reported Restructuring Costs for 1 consecutive years, with -$699000.0 the latest figure, recorded in Q4 2020.
- For the quarter ending Q4 2020, Restructuring Costs changed N/A year-over-year to -$699000.0; the trailing twelve-month figure through Dec 2020 stood at $50000.0 (changed N/A YoY), and the FY2021 full-year result was $216000.0, up 332.0% from the prior year.
- Restructuring Costs retreated to -$699000.0 in Q4 2020 per CMMB's latest filing, from $79000.0 in the prior quarter.
- Across five years, Restructuring Costs topped out at $670000.0 in Q1 2020 and bottomed at -$699000.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Chemomab Therapeutics | 17.03 Mn | 17.03 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | -699,000.00 |
| Sep 30, 2020 | 79,000.00 |
| Mar 31, 2020 | 670,000.00 |